Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
HOOK Stock News and Mentions of HOOKIPA Pharma Inc. Stocktwits
Updated: April 25, 2024 (01:57)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where HOOKIPA Pharma Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of HOOKIPA Pharma Inc. (HOOK).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the HOOKIPA Pharma stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of HOOKIPA Pharma Inc. (HOOK)
April 24, 2024 (14:31) / "Benzinga" (by Vandana Singh)
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? - HOOKIPA Pharma ( NASDAQ:HOOK )
Wednesday, HOOKIPA Pharma Inc HOOK received clearance from the FDA for its Investigational New Drug ( IND ) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers.
In Article Trend: Somewhat-Bullish
April 24, 2024 (11:01) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, April 24, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S.
In Article Trend: Neutral
April 16, 2024 (20:30) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NEW YORK and VIENNA, Austria, April 16, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Compensation Committee of the Company's Board of ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:56) / "Benzinga" (by Vandana Singh)
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients - Roche Holding ( OTC:RHHBY )
Monday, Roche Holdings AG RHHBY announced topline data from Phase 3 STARGLO study of Columvi ( glofitamab ) in combination with gemcitabine plus oxaliplatin ( GemOx ) versus MabThera/Rituxan ( rituximab ) in combination with GemOx in certain subset of patients with diffuse large B-cell lymphoma.
In Article Trend: Somewhat-Bullish
April 10, 2024 (11:01) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
NEW YORK and VIENNA, Austria, April 10, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, HOOKIPA or the Company ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA's Executive Team will ...
In Article Trend: Neutral
March 22, 2024 (12:15) / "Zacks Commentary" (by Zacks Equity Research)
HOOKIPA Pharma Inc. ( HOOK ) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 22, 2024 (11:01) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
NEW YORK and VIENNA, Austria, March 22, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth ...
In Article Trend: Neutral
March 13, 2024 (12:20) / "Zacks Commentary" (by Zacks Equity Research)
ADC Therapeutics SA ( ADCT ) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -119.15% and 1.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 6, 2024 (12:01) / "GlobeNewswire" (by HOOKIPA Pharma Inc)
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
NEW YORK and VIENNA, Austria, March 06, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's Chief Financial Officer, Reinhard Kandera, will ...
In Article Trend: Neutral
March 6, 2024 (12:01) / "Benzinga" (by Globe Newswire)
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference - HOOKIPA Pharma ( NASDAQ:HOOK )
NEW YORK and VIENNA, Austria, March 06, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. HOOK 'HOOKIPA' ) ) ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's Chief Financial Officer, Reinhard Kandera, will present ...
In Article Trend: Neutral
March 1, 2024 (11:49) / "Zacks Commentary" (by Zacks Equity Research)
Absci Corporation ( ABSI ) Surges 10.0%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website